Dependence of primary MM samples on antiapoptotic BCL2 molecules, according to molecular subgroups. (A) Analyses of BCL2, MCL1, or BCLXL dependencies of 60 patients with MM at diagnosis and relapse. Patients’ dependencies to BCL2, MCL1, or BCLXL were defined by cell death response to the respective BH3 mimetic in primary myeloma cells, as indicated in Figure 1B and Table 1. No^dep includes patient samples that are insensitive to each 1 of the 3 BH3 mimetics (Table 1). Fisher’s exact test was used for statistical analysis. (B) High and intermediate patients’ dependencies to MCL1 were analyzed at diagnostic versus relapse. Fisher’s exact test was used for statistical analysis. (C) Analyses of individual dependencies of 60 patients with MM at diagnosis and relapse. For each dependency, an arbitrary value was defined as follows: high dependency, 2; intermediate dependency, 1; no dependency, 0. The degree of dependency of each patient was indicated in Table 1. (D) BCL2 dependency was compared between CCND1⁺ and CCND1⁻ patients in the whole cohort (n = 47). (E) MCL1 dependency was analyzed in the CCND1, MMSET, and Others subgroups at diagnosis vs relapse. Fisher’s exact test was used for statistical analysis. (F) Percentage of no dependent patient samples was analyzed in translocated (CCND1/3, MAF, MMSET) and Others subgroups at diagnosis vs relapse. Fisher’s exact test was used for statistical analysis.